As part of ASPPH’s Now More Than Ever campaign, we are collecting powerful, real-world stories that show how public health impacts daily lives. These stories will be used in a national report, ...

Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (l ...